Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Phase II Study of AZD2171 in the Treatment of Patients With Acute Leukemia and Myelodysplastic Syndrome.

This phase II trial is studying how well cediranib maleate works in treating patients with relapsed, refractory, or untreated acute myeloid leukemia or high-risk myelodysplastic syndrome. Cediranib maleate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

Study Overview

• Status: Completed
• Conditions: Recurrent Adult Acute Myeloid Leukemia; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Previously Treated Myelodysplastic Syndromes; Secondary Myelodysplastic Syndromes; Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); de Novo Myelodysplastic Syndromes
• Intervention / Treatment: Other: laboratory biomarker analysis; Drug: cediranib maleate

Detailed Description

PRIMARY OBJECTIVES:

I. Evaluate the objective response rate in patients with relapsed, refractory, or untreated acute myeloid leukemia or high-risk myelodysplastic syndromes treated with AZD2171 (cediranib maleate).

SECONDARY OBJECTIVES:

I. Determine the toxicity of this drug in these patients. II. Determine the response duration, event-free survival, and overall survival of patients treated with this drug.

III. Determine the hematological response rate in patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to disease (acute myeloid leukemia vs myelodysplastic syndromes).

Patients receive oral cediranib maleate once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy at baseline and on day 28 for correlative studies. Samples are analyzed for circulating endothelial cells, VEGF receptor expression, and leukemic blasts via flow cytometry and microvessel density via histopathological techniques.

After completion of study treatment, patients are followed up at 3 months and then every 6 months for up to 2 years.

• Study Type: Interventional
• Enrollment (Actual): 39
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • District of Columbia
    • Washington, District of Columbia, United States, 20060
      • Howard University Hospital
  • Florida
    • Jacksonville, Florida, United States, 32224-9980
      • Mayo Clinic in Florida
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Wayne State University/Karmanos Cancer Institute
  • Wisconsin
    • Madison, Wisconsin, United States, 53792
      • University of Wisconsin Hospital and Clinics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically or cytologically confirmed acute myeloid leukemia (AML) ormyelodysplastic syndromes meeting 1 of the following criteria:

  • Relapsed AML meeting any of the following criteria:

    • Good-risk cytogenetics (inv[16], t[8;21], or t[15;17]) in second orgreater relapse

      • Patients with AML t(15;17) must have failed prior tretinoin and arsenic-containing regimens AND progressed orrelapsed within 12 months of therapy
    • In first or greater relapse

  • Resistant AML

    • Unable to achieve first complete remission after at least 2 inductionregimens

  • Untreated AML meeting any of the following criteria:

    • At least 60 years of age
    • Preceding MDS

  • MDS

    • International Prognosis Scoring System (IPSS) risk groupof intermediate-2 or higher
• Patients with relapsed disease after allogeneic hematopoietic stem cell transplantation (HSCT) must be off allimmunosuppressive medications for at least 30 days and have no symptoms orsigns of graft-vs-host disease

• No active CNS metastasis

  • Patients with clinical signs of CNS disease or a history of CNS diseasewithin the past 6 months are required to undergo lumbar puncture to excludeCNS involvement
• No symptomatic leukostasis or requirement for leukapheresis

• Not eligible for allogeneic HSCTAND no suitable donor at the time of study entry

  • Patients who areeligible for HSCT, informed of the option, and choose not to proceed to HSCTare allowed
• ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
• Bilirubin normal
• AST and/or ALT ≤ 2.5 times upper limit of normal
• Creatinine normal OR creatinine clearance ≥ 60 mL/min
• No proteinuria ≥ 1+ on 2 consecutive urinalysis taken ≥ 1 week apart
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No HIV positivity
• LVEF ≥ 45% by echocardiography
• Mean QTc ≤ 500 msec (with Bazett's correction)
• No other significant ECG abnormality
• No history of familial long QT syndrome
• No disseminated intravascular coagulation
• No history of allergic reactions attributed to compounds of similar chemical orbiological composition to AZD2171

• No concurrent uncontrolled illness, including, but not limited to, any of the following:

  • Hypertension
  • Thyroid disease
  • Ongoing or active infection
  • Symptomatic congestive heartfailure
  • Unstable angina pectoris
  • Cardiac arrhythmia

  • NYHA class III-IV heart disease

    • NYHA class II heart disease controlled with treatment allowed
  • Psychiatric illness or social situations that would limit study compliance
• See Disease Characteristics

• More than 4 weeks since prior chemotherapy (6 weeks fornitrosoureas or mitomycin C), radiotherapy, or major surgery and recovered

  • Hydroxyurea allowed to control peripheral blast count> 20,000/mcL prior to study entry and during the first 3 days of study therapy
• More than 4 weeks since prior and no concurrent growth factor or other cytokine support
• At least 30 days since prior investigational agents or participation in aninvestigational trial

• No more than 3 prior courses of induction chemotherapy

  • Induction chemotherapyis defined as that intended to induce complete remission and given at a time thatthe patient has active disease
• No concurrent CYP interactive medications
• No other concurrent investigational agents
• No concurrent drugs or biologics with proarrhythmic potential
• Prior and concurrent hydroxyurea allowed to control peripheral blast count> 20,000/mcL during the first 3 days of study therapy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment (enzyme inhibitor therapy); Patients receive oral cediranib maleate QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.	Other: laboratory biomarker analysis; Correlative studies; Drug: cediranib maleate; Given orally; Other Names: AZD2171; Recentin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Number of Confirmed Disease Response: Complete Response (CR), Partial Response (PR), and Hematologic Improvement (HI). A Confirmed Response is Defined to be an Objective Status of CR, PR, or HI Noted on 2 Consecutive Evaluations.	Complete Response (CR) requires a repeat bone marrow with < 5% myeloblasts, hemoglobin ≥ 11 g/dl, neutrophils ≥ 1000/mm3, platelets ≥ 100,000/mm3, and no circulating blasts. Partial Response (PR) requires a bone marrow blast reduction of 50% or more, hemoglobin ≥ 11 g/dl, neutrophils ≥ 1000/mm3, platelets ≥ 100,000/mm3, and no circulating blasts. Hematologic Improvement (HI) requires one of the following: RBC transfusion independent participants are required to have >1.5 g/dL increase in hemoglobin,; RBC transfusion-dependent participants are required to be transfusion independent,; A 100% increase, and an absolute increase over 500mm^3 in Absolute Neutrophil Count,; Participants with a pretreatment platelet count over 20,000/mm3 require an absolute increase of 30,000/mm^3 or more,; Participants with platelet count below 20,000/mm3 require an increase over 20,000/mm^3 and by at least 100%.	At the end of cycles 1 and 3 and every 3 cycles thereafter up to 26 cycles

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	Defined as the time from date of registration to date of death due to any cause or date last known alive. The distribution of survival time will be estimated using the method of Kaplan-Meier.	Every cycle during treatment and every 6 months for up to 2 years after completion of study treatment
Progression-free Survival	Defined as the time from date of registration to date that disease progression was documented, death, or last date that progression-free status was documented, whichever comes first. Estimated using the method of Kaplan-Meier. Disease progression is defined as one of the following: A ≥ 50% increase in bone marrow blasts from the best response, or; A 50% or greater decrement from maximum remission/response levels in neutrophils or platelets, or; A reduction in hemoglobin concentration by at least 1.5 g/dl, or; Transfusion dependence (without alternative explanation and sustained for at least 2 weeks).	Every 3 courses during treatment and then at 3 months and every 6 months for up to 2 years after completion of study treatment
Duration of Response	Measured from the time criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Estimated using the method of Kaplan-Meier.	Every 3 courses up to 26 courses
The Number of Patients That Report Adverse Events Possibly, Probably, or Definitely Related to AZD2171.	Graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. All adverse events determined to be possibly, probably, or definately related to AZD2171 are included in this analysis.	Continuously during treatment up to 26 courses

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Mark Juckett, Mayo Clinic

Study record dates

Study Major Dates

• Study Start: May 1, 2008
• Primary Completion (Actual): July 1, 2011
• Study Completion (Actual): March 1, 2012

Study Registration Dates

• First Submitted: May 16, 2007
• First Submitted That Met QC Criteria: May 16, 2007
• First Posted (Estimate): May 17, 2007

Study Record Updates

• Last Update Posted (Actual): February 15, 2017
• Last Update Submitted That Met QC Criteria: December 28, 2016
• Last Verified: December 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Disease; Bone Marrow Diseases; Hematologic Diseases; Neoplastic Processes; Precancerous Conditions; Syndrome; Myelodysplastic Syndromes; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Preleukemia; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Cediranib
• Other Study ID Numbers: NCI-2009-00129 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); P30CA015083 (U.S. NIH Grant/Contract); N01CM62205 (U.S. NIH Grant/Contract); CDR0000544833; MCCRC-MC048H; MC048H (Other Identifier: Mayo Clinic); 7135 (Other Identifier: CTEP)